Strong regulatory norms should be internalized by Indian pharma companies

26 February 2016

Building strong quality culture, adapting quality metrics, and demystifying data reliability issues were some of the broad issues discussed at the Indian Pharmaceutical Forum, organized by leading Indian pharma companies including Sun Pharmaceuticals, Lupin, Torrent, Cadila and Cipla.

The forum provided a platform to discuss ways to fix quality of drugs produced by leading drug regulators in the world including the US Food and Drug Administration, the UK's Medicine and Healthcare Products Regulatory Agency (MHRA) and India's Drug Controller, Drug Controller General of India (DGCI).

"Quality is not an Indian problem, but a global problem. India has not done very differently than US or Europe," Mathew Thomas, country director of the US FDA, stated.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK